BioSpace News Archive

Millstone Medical Outsourcing, the industry’s leading partner of choice for medical manufacturers’ post-manufacturing and aftermarket services, announces its completed acquisition of Ethide Labs on November 14, 2022.

Ventus Therapeutics, Inc. announced that its Head of In Vitro and In Vivo Pharmacology, Anick Auger, presented an overview of the company’s novel NLRP3 inhibitor programs at the Fourth Inflammasome Therapeutics Summit, held from Nov. 29 to Dec. 1 in Boston.

The research antibodies market is projected to grow at a rate of 5.9% in terms of value, from USD 3.35 Billion in 2019 to reach USD 5.33 Billion by 2030.

According to Nova one advisor, the global Immunohistochemistry market size was estimated at USD 2.75 billion in 2022 and is projected to hit around USD 4.19 billion by 2030, growing at a CAGR of 8.29% during the forecast period 2022 to 2030.

Brain Scientific, a Florida-based applied science technology company, announces a new distribution agreement with Fulcrum to drive sales, and the company further announces the hiring of Kevin Winterfield as vice president of marketing and communications to accelerate Brain Scientific’s strategic growth plan heading into the new year.

The global plasmid DNA manufacturing market size accounted for USD 446.13 million in 2022 and is expected to hold USD 2.156 million by 2030 with a CAGR of 21.7%. from 2022 to 2030

Pocket Naloxone Corp., a startup pharmaceutical company with the vision of enhancing naloxone delivery, today announced positive results from its human pharmacokinetic (PK) study of its novel naloxone nasal swab NaxSwab™.

Valitor, a biotechnology company engineering better medicines to conquer drug limitations, announced that its president and chief scientific officer, Wesley Jackson, Ph.D., will present at the Ophthalmology Innovation Source XII Summit in San Diego, CA on December 3, 2022.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted stock options to purchase an aggregate of 6,100 shares of Karyopharm’s common stock and an aggregate of 4,200 restricted stock units to two newly-hired employees.

Oncternal Therapeutics, Inc. today announced that it has granted an inducement award to one new employee, James Robinson, who joined Oncternal as Head of Biometrics & Data Sciences.